View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Carole Braudeau
  • Carole Braudeau

Credit Morning 05/15/2025

Maxeda: solid Q4 results and Q1 expected to be strong. Further bond buybacks.|Ubisoft: sharp decline in 2024/25 earnings, no rebound expected in 2025/26|Forvia is considering selling its spare parts division|Techem Q2 25 results: Good earnings print; ownership change and mandatory call remain open|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 15/05/2025

Maxeda : de bons résultats T4 et un T1 qui devrait l’être tout autant. Poursuite des rachats de dettes.|Ubisoft : résultats 2024/25 en forte baisse, pas de rebond attendu en 2025/26|Forvia envisagerait la cession de sa division de pièces détachées|Techem Q2 25 results: Good earnings print; ownership change and mandatory call remain open|

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/13/2025

Cellnex issues € 750m of new 2032 notes|Grifols : Q1 2025 earnings above expectations, FY guidance maintained despite weaker US dollar|90-day truce in the trade war between the United States and China|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 13/05/2025

Cellnex émet 750 m EUR de nouvelles obligations 2032|Grifols : résultats supérieurs aux attentes au T1 2025, guidance annuelle confirmée malgré la dépréciation du dollar US|Trêve de 90 jours dans la guerre commerciale entre les Etats-Unis et la Chine|

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)

Ahead of today’s signing of an Executive Order to introduce a Most Favoured Nation approach to drug pricing in the US, we show that net pricing in the EU is c.50% lower than in the US & which companies have most to lose from MFN. We also show that, in reality,

Carole Braudeau
  • Carole Braudeau

Credit Morning 05/08/2025

Branicks Q1 25 results: Further increase in vacancy; fundamentally not improving|Teva: Q1 2025 results up slightly. Strong momentum in innovative medicines and the new efficiency programme lend credibility to the 2027 guidance.|TPG steps away from Techem acquisition; documentation subject to special call|Banco BPM reports solid Q1 performance|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 08/05/2025

Branicks Q1 25 results: Further increase in vacancy; fundamentally not improving|Teva : résultats au T1 2025 en légère hausse. La bonne dynamique des médicaments innovants et le nouveau programme d’efficience crédibilisent la guidance 2027.|TPG steps away from Techem acquisition; documentation subject to special call|BPM publie un trimestre record et au-dessus des attentes|

Emmanuel Matot ... (+2)
  • Emmanuel Matot
  • Martin Marandon-Carlhian
Emmanuel Matot ... (+2)
  • Emmanuel Matot
  • Martin Marandon-Carlhian

Novartis AG: 1 director

A director at Novartis AG sold 21,000 shares at 94.000CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch